MedTrace Logo

A Study of LY2189102 in Patients With Type 2 Diabetes

NCT00942188 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2019-09-18

Study results available
· View outcomes & findings →

Summary

Study to evaluate the safety, tolerability and efficacy of LY2189102 in patients with type 2 diabetes.

Conditions

Interventions

DRUG

LY2189102

Participants received 2 subcutaneous (SC) injections weekly for 12 weeks.

DRUG

Placebo

Participants received 2 SC injections weekly for 12 weeks.

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00942188 on ClinicalTrials.gov